The report provides a detailed analysis essential for establishing a Vildagliptin production plant. It encompasses all critical aspects necessary for Vildagliptin production, including the cost of Vildagliptin production, Vildagliptin plant cost, Vildagliptin production costs, and the overall Vildagliptin production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Vildagliptin production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Vildagliptin is used in the treatment of type 2 diabetes mellitus; it is a common dipeptidyl peptidase-4 inhibitor. Its activity results from the increase of sensitivity of pancreatic islet beta cells to glucose and improvement in glycemic control. It can be used alone or in combination with other antidiabetic agents like metformin, sulfonylureas, or thiazolidinediones. It is characterized by weight neutrality/lipid sparing, minimal edema, and with no-severe hypoglycemia risk. It is utilized for dampening the endoplasmic reticulum stress and can help protect both β-cell function and β-cell mass in mild hyperglycemia. It has neuroprotective effects that can be utilized in easing cognitive problems in Alzheimer's disease as well as favorable in cardiovascular disorders.
The market of Vildagliptin is driven by several factors. Its use in the treatment of type 2 diabetes mellitus contributes to its increasing demand around the globe. The presence of numerous governmental initiatives for improving healthcare infrastructure makes it a popular product. Also, the scope of combination therapies and finding new drugs makes it a popular product among physicians for treating diabetic complications. Therefore, industrial Vildagliptin procurement is influenced by its worldwide demand for type 2 diabetes treatment, coupled with government initiatives in support, the potential for combination therapies, and benefits from outsourcing production.
Raw Material for Vildagliptin Production
According to the Vildagliptin production plant project report, the key raw materials used in the production of Vildagliptin include L-Proline-(1-Aminoadamantane Hydrochloride).
Production Process of Vildagliptin
The extensive Vildagliptin production cost report consists of the following major industrial production process:
- From L-Proline and 1-Aminoadamantane Hydrochloride: The industrial production process for Vildagliptin involves several steps. First, L-proline goes through hydroxylation introducing a hydroxyl group. After that, chloroacetylation takes place, adding a chloroacetyl group to the structure. This intermediate then goes through cyanation, adding a cyano group to it. Then, it is reacted with 1-amino adamantane hydrochloride for an amino substitution reaction, giving Vildagliptin as the final product.
Vildagliptin is a white solid. Its molecular formula is C17H25N3O2, and it has a molecular weight of around 303.40 g/mol. It has a melting point range of 153-155°C. It is sparsely soluble in water but soluble in DMSO, DMF, and ethanol. Its pKa value is around 15.05, making it relatively stable in different pH environments. It has a high absolute bioavailability of around 85%. It contains a nitrile group, and it is electrically active, showing irreversible oxidative-reductive cycles. All these physical and chemical properties contribute to its use treatment of type 2 diabetes mellitus.